Director/PDMR Shareholding | 28-Mar-2025 | 15:00 | RNS |
Form 8.5 (EPT/RI)-Advanced Medical Solutions Gro... | 28-Mar-2025 | 08:58 | GlobeNewswire NA |
Form 8.5 (EPT/RI)-Alliance Pharma plc | 28-Mar-2025 | 08:56 | GlobeNewswire NA |
Form 8.5 (EPT/RI)-Dowlais Group plc | 28-Mar-2025 | 08:54 | GlobeNewswire NA |
Form 8.5 (EPT/RI)-Thruvision Group plc | 28-Mar-2025 | 08:52 | GlobeNewswire NA |
Director/PDMR Shareholding | 27-Mar-2025 | 12:00 | RNS |
Transaction in Own Shares | 27-Mar-2025 | 11:00 | RNS |
Form 8.5 (EPT/RI) | 27-Mar-2025 | 08:48 | GlobeNewswire NA |
Form 8.5 (EPT/RI)-NIOX Group plc | 27-Mar-2025 | 08:42 | GlobeNewswire NA |
Form 8.5 (EPT/RI)-Dowlais Group plc | 27-Mar-2025 | 08:40 | GlobeNewswire NA |
Form 8.5 (EPT/RI)- Alliance Pharma plc | 27-Mar-2025 | 07:45 | GlobeNewswire NA |
Director/PDMR Shareholding | 26-Mar-2025 | 12:30 | RNS |
Form 8.5 (EPT/RI)-Thruvision Group plc | 26-Mar-2025 | 08:14 | GlobeNewswire NA |
Form 8.5 (EPT/RI)-De La Rue plc | 26-Mar-2025 | 08:12 | GlobeNewswire NA |
Form 8.5 (EPT/RI)-Alliance Pharma plc | 26-Mar-2025 | 08:09 | GlobeNewswire NA |
Currency | UK Pounds |
Share Price | 486.60p |
Change Today | -6.60p |
% Change | -1.34 % |
52 Week High | 623.00 |
52 Week Low | 484.20 |
Volume | 711,776 |
Shares Issued | 693.95m |
Market Cap | £3,376.75m |
RiskGrade | 206 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 3 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
Latest | Previous | |
---|---|---|
Interim | Final | |
Ex-Div | 12-Dec-24 | 22-Aug-24 |
Paid | 31-Dec-24 | 06-Sep-24 |
Amount | 16.50p | 19.00p |
Time | Volume / Share Price |
15:24 | 0 @ 487.20p |
16:35 | 301,842 @ 486.60p |
16:35 | 395 @ 486.60p |
16:35 | 1,039 @ 486.60p |
16:35 | 187 @ 486.60p |
CEO | Fani Titi |
Chair | Philip Hourquebie |
Finance Director | Nishlan Samujh |
You are here: research